Monthly Prescribing Reference

Biosimilars Mvasi, Kanjinti Now Available in the US

Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan. Mvasi, a ...
PharmiWeb

European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first ...
PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Amgen has become the first company to claim approval for a biosimilar cancer drug in the US, getting the nod for its version of Roche’s $7bn-a-year blockbuster Avastin. The FDA green light for Mvasi ...
GEN

After FDA Approval, Amgen–Allergan Cancer Biosimilar Mvasi Faces Launch, Pricing Challenges

Amgen and Allergan have won the first U.S. approval for a biosimilar cancer treatment following FDA authorization of their Mvasi™ (bevacizumab-awwb), a near-copy of Roche subsidiary Genentech’s ...
Business Insider

Amgen And Allergan's MVASI Gets EU Approval To Treat Certain Types Of Cancer

(RTTNews) - Amgen (AMGN) and Allergan plc. (AGN) announced Thursday that the European Commission has granted marketing authorization for MVASI (biosimilar bevacizumab). MVASI is the first biosimilar ...